title: Antiphospholipid antibody syndrome secondary to trimethoprim/sulfamethoxazole.
abstract: Antiphospholipid antibody syndrome (APS) results from autoantibodies to cell surface phospholipids or phospholipid-binding proteins resulting in clotting anomalies and can have devastating sequelae, including stroke, deep venous thrombosis, pulmonary embolism, and recurrent spontaneous abortions. However, cutaneous manifestations are the first sign of APS in up to 41% of patients. We present a case report of APS that developed several days after taking trimethoprim/sulfamethoxazole. The clinical and pathological features of this unique presentation, differential diagnoses, and treatments are discussed.
authors.affiliation: Department of Dermatology, St. Luke's-Roosevelt Hospital and Beth Israel Medical Centers, New York, NY 10025, USA. JonathanlSilverberg@gmail.com
authors.forename: Jonathan I
authors.initials: JI
authors.lastname: Silverberg
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Votava
authors.forename: Barry L
authors.initials: BL
authors.lastname: Smith
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects*; D016736:Antiphospholipid Syndrome / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D001323:Autoantibodies / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*
chemical_list: D000890:Anti-Infective Agents; D001323:Autoantibodies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination